학술논문
26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2023 20 Supplement
Subject
Language
ISSN
2590-0188